Medical Health & Life Science Research News

Cell line development market to grow at 13.0% CAGR during 2016 to 2023 just published

Growing incidence rates of cancer and auto immune disorders that needs effective and early treatment are the main factors driving the cell line development market throughout the forecast timeframe. Moreover, favorable government initiatives for the development of healthcare infrastructure and the advancement of new technologies is likely to fuel the industry.

Cell Line Development Market size will cross USD 7 billion by 2023; as per a new research report.

Advancement in methotrexate amplification (DHFR) technologies and glutamine synthetase (GS) technologies, growing demand for effective cancer treatment drive the growth of cell line development market in the coming years.

Request a Sample Copy of Global Cell Line Development Market Research Report @…utm_source=WAT-SP

The accessories and consumables segment is likely to grow at the fast rate over the forecast period due to increase in the usage rate of disposables for manufacturing vaccines and monoclonal antibodies. The mammalian source was the leading segment, owing to the high usage of mammalian cell line development techniques by many biopharmaceutical firms that are on the basis of methotrexate (MTX) amplification technology and glutamine synthetase (GS) system.

Bioproduction is anticipated to contribute for the major revenue share in the application area of the cell line development market. Owing to the presence of technologically advanced processes for large scale production of biologics, increase in R&D activities and introduction of biosimilars and drive the growth of the segment in the coming years.  

U.S. cell line development market led the North America segment. Increasing need for biologics, existence of enhanced healthcare infrastructure and growing awareness levels for cell therapy in the region are the important factors driving the growth of industry over the forecast period.

China and India is expected to grow at a lucrative revenue share over the forecast timeframe. Owing to the presence of high untapped opportunities, supportive government initiatives and increased investments by manufacturers and government in biotechnology sector fuel the demand for cell line development market.

Enquire on Global Cell Line Development Market Research Report @…utm_source=WAT-SP

Based on source, mammalian cells represent the dominant segment for recombinant protein production, owing to their large volume to assemble proteins and add human-like post-translational modifications.

Tissue engineering segment is expected to grow at a significant growth rate over the forecast timeframe. Rapid advancement in the stem cell research with a focus on their therapeutic potential for regenerative medicine and other biomedical applications drives the cell line development market growth.

Increasing prevalence of cancer with improved adoption of advanced technologies will drive U.S. cell line development market growth.

Brazil is anticipated to grow at a significant growth rate due to booming biotechnology and pharmaceutical industry in the country.

Companies operating in cell line development market are American Type Culture Collection (ATCC), Selexis, GE Healthcare, Lonza Group, Sartorious, WuXi AppTec, Thermo Fisher Scientific, European Collection of Cell Cultures (ECACC), Corning and Sigma-Aldrich Corporation. Key players are focusing on offering wide range of product and collaborative agreement, to sustain their leadership position.

Enquire Now @…sf/?utm_source=SP

News From

Market Size ForecastersMarket Size Forecasters
Category: Market Research Publishers and RetailersCompany about:, a Skyline Market Research LLP brand, is an online aggregator of market research reports. offers a comprehensive collection of full length reports on global and regional markets in 100+ industry verticals. We have partnered with some of the leading business and market research publishing houses and regularly update our online library to offer wide range of reports to our customers.
This email address is being protected from spambots. You need JavaScript enabled to view it.